MarketPulse

T cell engager

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Galapagos, Gilead in Advanced Talks on T-Cell Therapy Partnership

Galapagos and Gilead are in advanced partnership talks for a first-in-class T-cell engager for autoimmune diseases, with 50% cost-sharing and €500 million capital freed for Galapagos.
GILDGLPGstrategic partnershipclinical development
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Galapagos and Gilead Team Up on Breakthrough T Cell Engager for Autoimmune Diseases

Galapagos and Gilead plan to jointly develop an Ouro T cell engager for autoimmune diseases, splitting acquisition costs while Galapagos leads development and Gilead commercializes, freeing $500M in Galapagos cash.
GILDGLPGautoimmune diseasesorphan drug designation
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Molecular Partners Posts $61.7M Loss but Funds Pipeline Through 2028

Molecular Partners reports CHF 61.7M net loss but maintains CHF 93.1M cash runway through 2028, advancing Radio-DARPin and immuno-oncology pipeline programs.
MOLNfinancial resultsclinical trial